STAT July 14, 2020
Priscilla Velentgas and Karin de Haart

The pharma industry is in a mad dash to bring a Covid-19 vaccine to market, ideally before 2020 slips into 2021. This represents a dramatic acceleration from standard development timelines, which historically have often lasted 10 to 15 years. More than 100 Covid-19 vaccines are currently in development, with 21 already being tested in human clinical trials.

Regulatory agencies like the U.S. Food and Drug Administration are doing their part to accelerate the path to approval, allowing manufacturers to conduct animal studies in parallel with Phase 1 trials and outlining criteria for emergency authorization before full approval.

These efforts mean we could have a vaccine approved much sooner than was previously possible, which would be a powerful tool for resolving...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Public Health / COVID
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours

Share This Article